Brief Report

Eye is the Window to the Brain Pathology

Varun Kumar*

Department of Ophthalmology, Stanford University, School of Medicine, Stanford, CA, USA

*Corresponding author: Varun Kumar, Department of Ophthalmology, Stanford University, School of Medicine, Stanford, CA, USA, Tel: +1 2047871927; E-mail: vkumar2@stanford.edu

Citation: Kumar V (2017) Eye is the Window to the Brain Pathology. Curr Adv Ophthalmol 2017: 3-4. doi:https://doi.org/10.29199/CAOP.101013

Received: 25 September, 2017; Accepted: 31 October, 2017; Published: 15 November, 2017

In many neurological diseases, retina is affected leading to partial or complete vision loss, which further depends upon the severity of the disease. For example, majority of the stroke victims suffer vision loss due to stroke-induced retinal damage [1,2]. Similarly, there is an aggregation of toxic huntingtin protein [3], intra retinal amyloid deposition [4], and loss of retinal dopaminergic neurons [5] in mouse model of Huntington, Alzheimer and Parkinson’s disease respectively. These studies strongly suggest the association between brain and the eye. However, questions remain how important is the pathophysiological responses of the retina of the eye in understanding these neurological diseases? This has not been well investigated. Moreover, why eye is the mirror/window to the brain pathology? Part of the reason is the retina being a structure of the brain, which projects out of the diencephalon, have similar embryonic origin as brain, shares similar brain vasculature, blood barriers as well as pathophysiology. Moreover, earlier changes necessary to understand the pathophysiology of specific neurological diseases is easily demonstrated in the retina of the eye as described above.

Understanding the metabolic changes in the retina can be used not only as a biomarker for eye diseases but some prominent fatal diseases as well. For example, detection of homocysteine in the retina is a biomarker for age-related macular degeneration [6] but also, for cardiac diseases [7]. Proteomic analysis of the ocular fluid such as vitreous humor has provided exciting results for biomarkers to be used for detection or progression of many neurodegenerative diseases such as Alzheimer’s disease [8], glaucoma [9] etc. However, if we further understand the retina, questions remain how accurately earlier retinal changes can be used as biomarkers for predicting different neurological diseases? This is a very complex question and hard to answer because different diseases might have mixed effects on the retina. At this stage, it will be difficult to differentiate specific diseases associated changes in the retina.

However, there are some neurological diseases such as stroke, which greatly co-relates with retinal changes. For example, De Silva et al., demonstrated that patients with severe focal retinal arteriolar narrowing were highly susceptible to recurrent cerebrovascular events (stroke) as compared to those without arteriolar narrowing [10]. Moreover, retinal examination can also be useful for stroke risk stratification as well. For example, McGeechan et al., demonstrated that wider retinal venular caliber increases the risk of stroke in humans whereas the caliber of retinal arterioles was not associated with stroke [11]. They further put emphasis on considering inclusion of retinal venular caliber in prediction models containing stroke risk factors, which can reassign intermediate risk stroke category to lower risk. All the above studies strongly suggest that it will be worth understanding and imaging retina for early detection of pathophysiological changes after stroke. Similarly, Alzheimer’s disease is associated with significant loss of retinal ganglion cells, thinning of the retinal nerve fiber layer as well as optic nerve degeneration [12]. Using laser Doppler imaging device, Berisha et al., demonstrated a significant narrowing of the retinal veins and reduced venous blood flow in Alzheimer’s disease compared to healthy people [13]. Therefore, retinal vascular abnormality can be used as biomarker for Alzheimer’s disease. As evident, Alzheimer’s disease is characterized by b amyloid deposition. Using hyperspectral imaging, b amyloid having a unique hyperspectral signature, can be easily visualized in the retina, which can predict the occurrence of Alzheimer’s disease [14].

In conclusion, eye is one such organ of brain, which is easily accessible and shares similar vasculature, anatomy and physiology to the brain. Therefore, therapeutics effective in other neurological diseases might be used to reduce retinal damage and vice versa. Moreover, vision loss after many neurological diseases should not be neglected. In fact, the molecular changes in the retina can be used as a biomarker of neurological diseases such as Alzheimer’s and stroke, if tested appropriately.

References

  1. Ishikawa H, Caputo M, Franzese N, Weinbren NL, Slakter A, et al. (2013) Stroke in the eye of the beholder. Med Hypotheses 80: 411-415.
  2. Sabel BA, Henrich-Noack P, Fedorov A, Gall C (2011) Vision restoration after brain and retina damage: the “residual vision activation theory”. Prog Brain Res 192: 199-262.
  3. Karam A, Tebbe L, Weber C, Messaddeq N, Morlé L, et al. (2015) A novel function of Huntingtin in the cilium and retinal ciliopathy in Huntington’s disease mice. Neurobiol Dis 80: 15-28.
  4. Dutescu RM, Li QX, Crowston J, Masters CL, Baird PN, et al. (2009) Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer’s disease. Graefes Arch Clin Exp Ophthalmol 247: 1213-1221.
  5. Archibald NK, Clarke MP, Mosimann UP, Burn DJ (2009) The retina in Parkinson’s disease. Brain 132: 1128-1145.
  6. Huang P, Wang F, Sah BK, Jiang J, Ni Z, et al. (2015) Homocysteine and the risk of age-related macular degeneration: a systematic review and meta-analysis. Sci Rep 5: 10585.
  7. Ganguly P, Alam SF (2015) Role of homocysteine in the development of cardiovascular disease. Nutr J 14: 6.
  8. Butterfield DA (2004) Proteomics: a new approach to investigate oxidative stress in Alzheimer’s disease brain. Brain Res 1000: 1-7.
  9. Tezel G (2013) A proteomics view of the molecular mechanisms and biomarkers of glaucomatous neurodegeneration. Prog Retin Eye Res 35: 18-43.
  10. De Silva DA, Manzano JJ, Liu EY, Woon FP, Wong WX, et al. (2011) Retinal microvascular changes and subsequent vascular events after ischemic stroke. Neurology 77: 896-903.
  11. McGeechan K, Liew G, Macaskill P, Les Irwig, Ronald Klein, et al. (2009) Prediction of incident stroke events based on retinal vessel caliber: a systematic review and individual-participant meta-analysis. Am J Epidemiol 170: 1323-1332.
  12. Hinton DR, Sadun AA, Blanks JC, Miller CA (1986) Optic-nerve degeneration in Alzheimer’s disease. N Engl J Med 315: 485-487.
  13. Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL (2007) Retinal abnormalities in early Alzheimer’s disease. Invest Ophthalmol Vis Sci 48: 2285-2289.
  14. More SS, Beach JM, Vince R (2016) Early Detection of Amyloidopathy in Alzheimer’s Mice by Hyperspectral Endoscopy. Invest Ophthalmol Vis Sci 57: 3231-3238.